ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Tarsus Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 31.05%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 3 consecutive quarters
- ROCE(HY) Highest at -31.46%
- NET SALES(Q) Highest at USD 102.66 MM
- OPERATING PROFIT MARGIN(Q) Highest at -21.17 %
2
Rising Promoter Confidence
- Promoters have increased their stake in the company by 1.07% over the previous quarter and currently hold 8.23% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
3
Market Beating performance in long term as well as near term
- Along with generating 63.25% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Tarsus Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Tarsus Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Tarsus Pharmaceuticals, Inc.
62.36%
2.90
49.49%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
51.94%
EBIT Growth (5y)
-323.97%
EBIT to Interest (avg)
-28.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0.31
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.39
EV to EBIT
-13.83
EV to EBITDA
-14.01
EV to Capital Employed
218.48
EV to Sales
6.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1579.81%
ROE (Latest)
-30.08%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
ROCE(HY)
Highest at -31.46%
NET SALES(Q)
Highest at USD 102.66 MM
OPERATING PROFIT MARGIN(Q)
Highest at -21.17 %
RAW MATERIAL COST(Y)
Fallen by -1.4% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 6.47 times
OPERATING PROFIT(Q)
Highest at USD -21.73 MM
PRE-TAX PROFIT(Q)
Highest at USD -20.34 MM
NET PROFIT(Q)
Highest at USD -20.34 MM
EPS(Q)
Highest at USD -0.48
-7What is not working for the Company
INTEREST(HY)
At USD 4.45 MM has Grown at 44.02%
DEBT-EQUITY RATIO
(HY)
Highest at -92.81 %
Here's what is working for Tarsus Pharmaceuticals, Inc.
Net Sales
At USD 102.66 MM has Grown at 75.73%
over average net sales of the previous four periods of USD 58.42 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Sales
Highest at USD 102.66 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -21.17 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Operating Profit
Highest at USD -21.73 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -20.34 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -20.34 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.48
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Inventory Turnover Ratio
Highest at 6.47 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -1.4% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Tarsus Pharmaceuticals, Inc.
Interest
At USD 4.45 MM has Grown at 44.02%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -92.81 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
